Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apo805K1 in moderate to severe chronic plaque psoriasis
NCT01483924Phase 2Completed
- Sponsor
- ApoPharma Inc.
- Start
- Nov 2011
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of orilotimod in plaque psoriasis, sponsored by ApoPharma Inc. Primary endpoint: Number of Patients With Adverse Events at 12 weeks. Started Nov 2011; status: completed.
02
Drugs
orilotimod
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01483924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01483924.